Loading...
OTCM
NTII
Market cap0USD
Apr 30, Last price  
0.00USD
Name

Neurobiological Technologies Inc

Chart & performance

D1W1MN
OTCM:NTII chart
P/E
0.00
P/S
0.00
EPS
0.12
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
26m
+78.52%
200,000700,000506,242407,3072,100,00099,54414,781,25001,979,6392,786,5793,099,51112,338,61217,673,00014,760,00026,350,000
Net income
3m
P
-3,700,000-5,300,000-5,211,443-7,368,588-2,173,204-3,692,233-3,114,7321,588,391-4,266,355-2,686,468-1,808,103-24,977,567-27,838,954-14,128,000-16,322,0003,123,000
CFO
-16m
L-20.62%
-3,600,000-4,900,000-5,138,604-6,976,425-2,390,860-3,197,997-3,175,0501,371,824-3,912,572-3,110,127-2,078,035-9,404,3559,001,177-13,154,000-20,697,000-16,429,000
Dividend
Dec 18, 20120.05 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Neurobiological Technologies, Inc. (NTII) is currently undergoing a liquidation and dissolution process, a plan that received stockholder endorsement in October 2009. In its earlier operations, the company's core focus was on the development of experimental pharmaceutical treatments for various human ailments. This firm, which was established in 1987, has its primary location in Emeryville, California.

Key people

Matthew Loar
Acting Chief Executive and Financial Officer, Director · since 2010
William Fletcher
Director · since 2009
John Stuppin
Director · since 1994
URL
IPO date
Feb 16, 1994
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show